Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study-Reference-Cited by-同舟云学术

Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study

Published:2020-02 Issue:2 Volume:2 Page:e84-e98
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Pawar Ajinkya,Desai Rishi J,Gautam Nileesa,Kim Seoyoung C

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference30 articles.

1. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, double-blind, randomized controlled trial;Fleischmann;Arthritis Rheumatol,2019

2. Baricitinib versus placebo or adalimumab in rheumatoid arthritis;Taylor;N Engl J Med,2017

3. Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients;Desai;J Manag Care Spec Pharm,2017

4. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis;Au;Ann Rheum Dis,2011

5. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials;Strand;Arthritis Res Ther,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib;Arthritis Research & Therapy;2024-08-27

2. Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance;Rheumatology and Therapy;2024-07-26

3. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

4. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23

5. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits;Current Rheumatology Reports;2023-12